Mesoblast (MESO) said late Wednesday it is expanding coverage for Ryoncil to 104 million lives in the US insured by government and commercial payers.
Ryoncil is the first mesenchymal stromal cell treatment approved by the US Food and Drug Administration, according to the firm.
Price: 10.62, Change: +0.31, Percent Change: +2.96
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.